Skip to main content
Top
Published in: Gastric Cancer 2/2013

01-04-2013 | Original Article

Gastric cancers with microsatellite instability exhibit high fluorodeoxyglucose uptake on positron emission tomography

Authors: Hyun Woo Chung, Sun-Young Lee, Hye Seung Han, Hyun Sik Park, Jae Hoon Yang, Hak Hyun Lee, Young So

Published in: Gastric Cancer | Issue 2/2013

Login to get access

Abstract

Background

Gastric cancers exhibit various degrees of 18F-fluorodeoxyglucose (FDG) uptakes on positron emission tomography/computed tomography (PET/CT) imaging. The aim of this study was to evaluate whether FDG uptake in gastric cancer varies according to the microsatellite instability (MSI) status.

Methods

Consecutive gastric cancer patients who underwent PET/CT imaging and MSI analysis were included in the study. The maximum standardized uptake value (SUVmax) of gastric cancer was assessed using PET/CT imaging.

Results

Of 131 gastric cancers, 16 exhibited a high incidence of MSI (MSI-H) and 3 exhibited a low incidence of MSI (MSI-L). In 29 subjects who showed no uptake on PET/CT imaging the gastric cancers were all microsatellite stable (MSS). Gastric cancers with MSI were related to age older than 60 years (p = 0.002), cancer volume larger than 10 cm3 (p = 0.015), and the presence of FDG uptake on PET/CT imaging (p = 0.001). A higher SUVmax of gastric cancer was linked to the presence of MSI (p < 0.001).

Conclusion

The presence of MSI is related to FDG uptake in gastric cancer. Care should be taken with MSS gastric cancers, because they show lower SUVmax on PET/CT imaging than MSI gastric cancers.
Literature
1.
go back to reference Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–64.PubMedCrossRef Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–64.PubMedCrossRef
2.
go back to reference Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758–62.PubMed Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758–62.PubMed
3.
go back to reference Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9:192–6.PubMedCrossRef Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9:192–6.PubMedCrossRef
4.
go back to reference De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging. 2002;29:525–9.PubMedCrossRef De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging. 2002;29:525–9.PubMedCrossRef
5.
go back to reference Yoshioka T, Yamaguchi K, Kubota T, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44:690–9.PubMed Yoshioka T, Yamaguchi K, Kubota T, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44:690–9.PubMed
6.
go back to reference Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136:1929–35.PubMedCrossRef Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136:1929–35.PubMedCrossRef
7.
go back to reference Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012–8.PubMedCrossRef Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012–8.PubMedCrossRef
8.
go back to reference Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006;33:148–55.PubMedCrossRef Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006;33:148–55.PubMedCrossRef
9.
go back to reference Takahashi H, Ukawa K, Ohkawa N, Kato K, Hayashi Y, Yoshimoto K, et al. Significance of (18)F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med. 2009;23:391–7.PubMedCrossRef Takahashi H, Ukawa K, Ohkawa N, Kato K, Hayashi Y, Yoshimoto K, et al. Significance of (18)F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med. 2009;23:391–7.PubMedCrossRef
10.
go back to reference Hur H, Kim SH, Kim W, Song KY, Park CH, Jeon HM. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. World J Surg Oncol. 2010;8:86.PubMedCrossRef Hur H, Kim SH, Kim W, Song KY, Park CH, Jeon HM. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. World J Surg Oncol. 2010;8:86.PubMedCrossRef
11.
go back to reference Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009;35:449–55.PubMedCrossRef Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009;35:449–55.PubMedCrossRef
12.
go back to reference Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer. 2007;97:1493–8.PubMedCrossRef Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer. 2007;97:1493–8.PubMedCrossRef
13.
go back to reference Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006;20:597–604.PubMedCrossRef Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006;20:597–604.PubMedCrossRef
14.
go back to reference Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med. 2003;30:288–95.CrossRef Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med. 2003;30:288–95.CrossRef
15.
go back to reference Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol. 2006;4:416–25.PubMedCrossRef Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol. 2006;4:416–25.PubMedCrossRef
16.
go back to reference Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem. 1996;377:675–84.PubMed Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem. 1996;377:675–84.PubMed
17.
go back to reference Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu Rev Genet. 1999;33:533–64.PubMedCrossRef Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu Rev Genet. 1999;33:533–64.PubMedCrossRef
18.
go back to reference Chong JM, Fukayama M, Hayashi Y, Takizawa T, Koike M, Konishi M, et al. Microsatellite instability in the progression of gastric carcinoma. Cancer Res. 1994;54:4595–7.PubMed Chong JM, Fukayama M, Hayashi Y, Takizawa T, Koike M, Konishi M, et al. Microsatellite instability in the progression of gastric carcinoma. Cancer Res. 1994;54:4595–7.PubMed
19.
go back to reference Wirtz HC, Müller W, Noguchi T, Scheven M, Rüschoff J, Hommel G, et al. Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res. 1998;4:1749–54.PubMed Wirtz HC, Müller W, Noguchi T, Scheven M, Rüschoff J, Hommel G, et al. Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res. 1998;4:1749–54.PubMed
20.
go back to reference Wu MS, Lee CW, Chun CT, Wang HP, Lee WJ, Chang MC, et al. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotype. Genes Chromosomes Cancer. 2000;27:403–11.PubMedCrossRef Wu MS, Lee CW, Chun CT, Wang HP, Lee WJ, Chang MC, et al. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotype. Genes Chromosomes Cancer. 2000;27:403–11.PubMedCrossRef
21.
go back to reference Liu P, Zhang XY, Shao Y, Zhang DF. Microsatellite instability in gastric cancer and precancerous lesions. World J Gastroenterol. 2005;11:4904–7.PubMed Liu P, Zhang XY, Shao Y, Zhang DF. Microsatellite instability in gastric cancer and precancerous lesions. World J Gastroenterol. 2005;11:4904–7.PubMed
22.
go back to reference Kawamura A, Adachi K, Ishihara S, Katsube T, Takashima T, Yuki M, et al. Correlation between microsatellite instability and metachronous disease recurrence after endoscopic mucosal resection in patients with early stage gastric carcinoma. Cancer. 2001;91:339–45.PubMedCrossRef Kawamura A, Adachi K, Ishihara S, Katsube T, Takashima T, Yuki M, et al. Correlation between microsatellite instability and metachronous disease recurrence after endoscopic mucosal resection in patients with early stage gastric carcinoma. Cancer. 2001;91:339–45.PubMedCrossRef
23.
go back to reference Choe WH, Lee SY, Lee JH, Shim SG, Kim YH, Rhee PL, et al. High frequency of microsatellite instability in intestinal-type gastric cancer in Korean patients. Korean J Intern Med. 2005;20:116–22.PubMedCrossRef Choe WH, Lee SY, Lee JH, Shim SG, Kim YH, Rhee PL, et al. High frequency of microsatellite instability in intestinal-type gastric cancer in Korean patients. Korean J Intern Med. 2005;20:116–22.PubMedCrossRef
24.
go back to reference Tessem MB, Selnaes KM, Sjursen W, Tranø G, Giskeødegård GF, Bathen TF, et al. Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res. 2010;9:3664–70.PubMedCrossRef Tessem MB, Selnaes KM, Sjursen W, Tranø G, Giskeødegård GF, Bathen TF, et al. Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res. 2010;9:3664–70.PubMedCrossRef
25.
go back to reference Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14:13–21.PubMedCrossRef Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14:13–21.PubMedCrossRef
26.
go back to reference Yasuda S, Takechi M, Ishizu K, Tanaka A, Maeda Y, Suzuki T, et al. Preliminary study comparing diffuse gastric FDG uptake and gastritis. Tokai J Exp Clin Med. 2008;33:138–42.PubMed Yasuda S, Takechi M, Ishizu K, Tanaka A, Maeda Y, Suzuki T, et al. Preliminary study comparing diffuse gastric FDG uptake and gastritis. Tokai J Exp Clin Med. 2008;33:138–42.PubMed
27.
go back to reference Wang Y, Shinmura K, Guo RJ, Isogaki J, Wang DY, Kino I, Sugimura H. Mutational analyses of multiple target genes in histologically heterogeneous gastric cancer with microsatellite instability. Jpn J Cancer Res. 1998;89:1284–91.PubMedCrossRef Wang Y, Shinmura K, Guo RJ, Isogaki J, Wang DY, Kino I, Sugimura H. Mutational analyses of multiple target genes in histologically heterogeneous gastric cancer with microsatellite instability. Jpn J Cancer Res. 1998;89:1284–91.PubMedCrossRef
Metadata
Title
Gastric cancers with microsatellite instability exhibit high fluorodeoxyglucose uptake on positron emission tomography
Authors
Hyun Woo Chung
Sun-Young Lee
Hye Seung Han
Hyun Sik Park
Jae Hoon Yang
Hak Hyun Lee
Young So
Publication date
01-04-2013
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 2/2013
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-012-0165-2

Other articles of this Issue 2/2013

Gastric Cancer 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.